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Abstract
Controlled-release drug delivery systems are capable of treating debilitating diseases,
including cancer. Brain cancer, in particular glioblastoma multiforme (GBM), is
an extremely invasive cancer with a dismal prognosis. The use of drugs capable of
crossing the blood-brain barrier has shown modest prolongation in patient survival,
but not without unsatisfactory systemic, dose-limiting toxicity. Localized delivery
of potent chemotherapeutics aims to lower systemic toxicity while increasing drug
concentrations directly to the tumor site. I have developed implantable drug delivery
microcapsule devices for the localized delivery of temozolomide and for treatment of
glioblastoma multiforme in this work. I have been able to modulate the drug release
profiles from these microcapsules based on the physical chemistry of the drug and the
dimensions of the release orifices in these devices. Experimental in vitro studies were
performed in order to test the function, reliability, and drug release kinetics of the
devices. The experimental release curves showed mass flow rates of 36 ug/hr for single-
orifice devices and an 88 ug/hr mass flow rate for multiple-orifice devices loaded with
temozolomide. Intracranial temozolomide-filled microcapsules were tested in a rodent
9L glioma model. Outcomes were animal survival and immunohistochemical analysis
of tissue for evidence of DNA strand breaks via terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) assay. Results showed that localized delivery of
chemotherapeutics from microcapsule devices is capable of prolonging animal survival
and may offer an alternative to the harsh side-effects and low response rates inherent
to systemic drug administration in GBM patients.
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Chapter 1
Background
1.1 Introduction
The broad motivation of this work is to design and develop a polymeric, diffusion-
based drug delivery microcapsule for localized treatment of human disease. This thesis
discusses the more specific aim of designing such devices for treatment of glioblas-
toma multiforme (GBM), a debilitating form of brain cancer. An understanding of
both GBM biology and the current state-of-the-art in GBM tumor maintenance and
treatment will help to determine drug delivery methods with high clinical relevance
that will guide the design of these devices.
The chemotherapeutic drugs of interest to this project are temozolomide (TMZ)
and doxorubicin hydrochloride (DOX). Studies detailing the physical chemistry of
these drugs, along with the engineering principles of small molecule diffusion, will al-
low for the fabrication of drug delivery devices that can deliver virtually any drug for-
mulation over a chosen period of time. Liquid crystal polymer (LCP) and poly(L)lactic
acid (PLLA) polymers will serve as the housing and vehicle for drug release. In vitro
drug release studies will be performed in order to test the function, reliability, and
drug release kinetics of the devices prior to in vivo efficacy studies that will be per-
formed in an intracranial rodent model of GBM. The results of these experiments will
shed light on the feasibility of treating GBM through localized delivery of chemother-
apeutic agents.
1.2 Glioblastoma Multiforme
1.2.1 Classification
Tumors of the central nervous system (CNS) represent a group of neoplasms that
have a wide range of genetic heterogeneity, are extremely difficult to classify, and
currently have no curative options. The World Health Organization (WHO) classifies
tumors of the CNS into nine categories according to the cell of tumor origin [1]. The
classification of astrocytic tumors includes the degree of tumor "aggressiveness." Rela-
tively slower-growing astrocytic tumors are termed "low-grade" tumors, whereas more
rapidly-growing tumors are "high-grade." Tumor progression from low to high-grade
status is associated with increased mitotic index, vascular endothelial proliferation,
and necrosis [2]. High-grade astrocytic tumors most commonly include anaplastic
(undifferentiated) astrocytomas (AA) and glioblastoma multiforme (GBM). These
tumors are also referred to as malignant gliomas due to their biological classification
as glial cells. GBM diagnosis is associated with the worst prognosis of all brain tumors
and is the focus of the work performed in this thesis.
The World Health Organization further categorizes astrocytic tumors into four
classes, or grades, with GBM being the most invasive and malignant type (grade IV).
Tumors of the other three grades are pilocytic astrocytomas (grade I), astrocytomas
(grade II), and anaplastic astrocytomas (grade III) [3]. GBM is the most frequent
primary malignant brain tumor, accounting for 12-15% of all brain tumors, and 60-
75% of astrocytic tumors [4]. The prevalence of GBM in the Western hemisphere
is about 3-4/100,000 new cases per year [4]. GBM occurs in patients of all ages,
races, and genders but is more common among Caucasians. Men have a higher GBM
mortality rate than women by a ratio of (3:2) [5][1]. GBM occurrence is rare below
the age of 40 and is most prevalent in the later years of life with a peak at 50 years
of age [5]. Pediatric patients are also more susceptible to development of malignant
GBM than younger adult patients, and occurrence rates plateau in people over 70
years of age [1].
The relatively high prevalence of GBM among brain tumor patients is unfortu-
nate due to the dismal prognosis that accompanies these neoplasms. Median patient
survival is estimated to be between 12 and 18 months when patients receive maxi-
mal treatment. This treatment includes surgical resection, radiation treatment, and
usually chemotherapy [6]. There have been few reports of complete GBM regression;
the overall 5-year survival rate is less than 10%, and the final mortality rate for all
patients is close to 100% [6]. The need for novel treatment strategies for primary and
recurrent GBM is crucial to the lives of these patients.
1.2.2 Natural History
Recent research has focused on the hypothesis that GBM tumor masses contain a
sub-population of cells with heterogenous genotypic and phenotypic traits. This het-
erogeneity is due to the complex genetic alterations that occur during GBM formation
from properly-functioning astrocytes. Inactivation of tumor suppressor genes along
with oncogene activation and overexpression are common traits in malignant glioma
[1]. A proposed schematic of the genetic pathways involved in astrocyte-to-GBM
transformation is shown in Figure 1-1[2]. Figure 1-1 shows that genetic mutations
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Figure 1-1: GBM development pathway
[2]
cause formation of malignant gliomas, and it has been hypothesized that an even
larger number of genes may be involved. Mutations in the genetic profile of GBM
cells also contribute to their chemotherapeutic resistance by inducing alterations in
genes that protect against cell death [2]. The expression of multi-drug resistance
genes (MDR) and 06-methylguanine-methyltransferase (MGMT) are associated with
the expression of chemoresistance phenotypes [2].
Genetic mutations in GBM induce the overexpression of specific growth factors
that facilitate the formation of new blood vessels through the process of angiogenesis.
Fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) are
two common mediators of angiogenesis [1]. Glioma cells are able to increase their
oxygen and nutrient supply by forming new blood vessels, which facilitate a greater
chance of tumor cell survival. Drugs such as Avastin are being investigated for their
ability of block VEGF and stop the production of blood vessels.
The high mortality rate associated with GBM is also attributed to a multitude of
physical properties that are unique to these gliomas. The most significant of these
properties is the unsatisfactory spatial location and orientation of the malignancy.
GBM occurs most frequently in the frontal and temporal lobes of the brain but can
often invade the basal ganglia and brain stem [5]. GBM may also appear in the central
part of the brain with a characteristic "butterfly" pattern that occupies the corpus
callosum and extends bilaterally into the centrum semiovale of both hemispheres [5].
The invasive nature of GBM is problematic. Research has suggested that gliomas
are capable of moving throughout the brain through chemical modulation of the sur-
rounding extracellular matrix (ECM). The processes through which tumor cells are
able to control such migration is not fully understood, but the migration is thought to
occur through the secretion of metalloproteases that cause degradation of the ECM[1].
Surgical resection has been shown to improve patient survival[2], but GBM commonly
spreads to invade eloquent areas of the brain where surgeons are unable to operate be-
cause such operations would substantially decrease neurological function and patient
quality-of-life (QOL). This spreading results in minimal surgical debulking, which in
turn leaves a substantial amount of tumor mass unaddressed. The residual tumor
cells are then able to migrate throughout the brain tissue, causing the high incidence
of GBM recurrence. Surgical intervention is even more difficult when the GBM tumor
mass contains diffuse, ill-defined physical boundaries[5].
1.2.3 Tumor Recurrence
Recurrence of GBM following surgical resection contributes substantially to the un-
favorable prognosis associated with these malignancies. Despite extensive surgical
intervention, GBM recurrence is inevitable after a median patient survival time of 32
to 36 weeks, and it has been reported that 90% of patients with glioma will experi-
ence tumor recurrence near the original tumor location [6][6]. Not all tumors recur
at the original tumor site. Studies have shown that the most common site of GBM
recurrence is 2 to 3 cm from the border of the original lesion[6].
Treatment strategies for recurrent GBM are confounded by the lack of uniform
definition and criteria of recurrent GBM, institutional variability in treatment, and
the heterogenous nature of recurrence in terms of glioma spatial location and acquired
resistance to chemotherapy. Researchers and clinicians usually define GBM recurrence
as a change from a previous interval of tumor absence or a loss of prior complete
tumor control [6]. These requirements are too vague, and a more definite set of
criteria need to be established in order to treat patients in a consistent manner. It
would otherwise not be possible to compare clinical trials from different institutions
without substantial doubt as to what form of GBM (primary or recurrent) is being
examined.
1.3 Treatment Options
1.3.1 Surgical Resection
The treatment of GBM has classically included surgery followed by radiation therapy.
Surgical intervention is crucial because it provides clinicians with tissue samples that
are used to confirm the histological status and malignancy of the tumor. This allows
for a more robust diagnosis than that obtained by most imaging techniques [6]. The
extent of surgical resection has been proven to be an important prognostic factor in
treating GBM patients. A retrospective analysis by the Montreal Neurological Insti-
tute showed that patients who had complete surgical resection had a better overall
prognosis that those with incomplete tumor resection [7]. Surgery can also confirm
tumor recurrence, reduce intracranial pressure and mass effect, improve patients'
neurological status, and improve efficacy of adjunctive therapy [1] [6]. Controversy
between institutions exists about the absolute degree of tumor resection that will
meaningfully change outcome, but it is widely accepted that even minimal surgical
intervention should be performed whenever possible.
1.3.2 Radiation
Whole-brain and localized radiation treatment is usually carried out with x-rays pro-
duced by linear accelerators. Three-dimensional imaging techniques are commonly
used for localized radiation treatment. Localized treatment is especially beneficial for
patients whose tumor mass is located in operable locations or if the lesion is relatively
small. Radiation dosage is limited by the tissue tolerance of normal white brain mat-
ter, and a cumulative dose of 60 Gy[1] is usually given over a prescribed time period.
Radiation-induced tissue necrosis is the primary side-effect and limiter to radiation
treatment.
Interstitial brachytherapy and gamma knife radiosurgery are two of the most
common types of localized radiation treatment for GBM. Stereotactic surgical proce-
dures allow for the placement of either removable or permanent Iodine-125 interstitial
brachytherapy radiation sources. Permanent interstitial sources have been found to
be safer than removable sources due to the high incidence of late-term radiation in-
jury from removable sources [1]. Studies have reported a median survival time of 9.1
months in patients with recurrent GBM when brachytherapy was used. A 3-year sur-
vival rate of 15% was also achieved against recurrent GBM treated with high-activity
Iodine-125 radio sources [6]. Infection, edema, radiation toxicity, and tissue necrosis
are the primary risks associated with interstitial brachytherapy.
Gamma knife radiosurgery is especially useful in addressing small lesions with
unsatisfactory spatial orientation in the brain. Radiosurgery is a non-invasive tech-
nique that typically requires placement of the skull in a stereotaxic frame. It allows
multiple radiation source beams to converge on a small target GBM lesion to produce
localized irradiation [1]. The Gamma Knife radiosurgery system by AB Elekta and
modified linear accelerators have been used as radiosurgery instruments. Risks to
the patient are similar to those of interstitial brachytherapy; local radiation-induced
tissue necrosis is the most common and damaging side-effect.
1.3.3 Chemotherapy
Chemotherapy is a versatile treatment strategy that allows for the development of
novel therapies against malignant gliomas. Chemotherapeutic agents are commonly
administered following surgical resection and irradiation of GBM lesions. Drugs may
be given systemically or directly to the tumor bed. Some chemotherapeutics act as
"radiosensitizers" that enhance the effect of radiation therapy and are given concomi-
tantly with radiation treatment.
A range of chemotherapeutic drugs have been investigated for action against GBM
in vitro and in vivo. A sample list of these drugs is given in Table 1-1. The three main
cytotoxic mechanisms through which chemotherapeutic drugs act are DNA damage,
DNA replication inhibition, and cytoskeletal disruption. An extensive review of each
of the chemotherapies presented in Table 1-1 is beyond the scope of this thesis, and
the discussion will instead focus on the drugs that are most clinically relevant to
current GBM treatment. The drugs used in this work are temozolomide (TMZ) and
doxorubicin hydrochloride (DOX). Carmustine (BCNU) will also be discussed due
to its historical importance as a chemotherapeutic agent against GBM and its use
in the development of novel drug delivery strategies. The cytotoxic mechanisms of
BCNU, TMZ, and DOX have been studied extensively and will be briefly discussed
in the following sections. Satisfactory delivery of these agents (systemic vs. localized
treatment) is of the utmost concern in treating GBM and is the underlying motivation
for the research and development of the drug delivery microcapsules described in this
thesis.
DNA damaging agents
Nitrosoureas
Carmustine (BNCU)
Lomustine (CCNU)
Nimustine (ACNU)
Semustine (MeCCNU)
PCNU
Platinum compounds
Cisplatin (CDDP)
Carboplatin
Nitrogen mustards
Cyclophosphamide (CPA)
Melphalan
Ifosfamide
Mafosphamide
Antibiotics
Bleomycin
Doxorubicin
Actinomycin D
Aziridinylbenzoquinon (AZQ)
Epirubicin
Others
Temozolomide
Procarbazine
Dacarbazine
Thiopeta
Chlorambucil
Busulfan
Spirohydantoin mustard (SHM)
DNA replication inhibitors
Topoisomerase inhibitors
Etoposide
Teniposide
Topotecan
Antimetabolites
Methotraxate (MTX)
5-Fluorouracil (5-FU)
Cytarabine (Ara-C)
5-Fluorocytosine (5-FC)
6-Tioguanine
lododeoxyuridine
Methylprednisolone
Bromodeoxyuridine
Cytoskeletal disrupting agents
Vinca alkaloids
Vinblastine
Vincristine
Taxenes
Paclitaxet
Docetaxel
Miscellaneous agents
Tamoxifen
Bryostatin
7-Hydroxystaurosporine (UCN-01)
Leflunomide (SU-101)
Mitoxantrone
Lovastatin
Table 1.1: Chemotherapeutic Drugs used for Treatment of GBM
[2]
Carmustine
Carmustine (BCNU) (1-3-bis(2-chloroethyl)-1-nitrosourea) had historically been the
focus of major study as it was one of the first chemotherapeutic drugs approved for
brain tumor treatment [8]. Initial clinical trials of BCNU against brain tumors began
in 1964, and FDA approval was granted in March 1977. Clinical trials also showed
that BCNU administration produced a survival advantage of an additional 2 months
when compared with radiation therapy alone [8].
The primary cytotoxic mechanism induced by BCNU is the cross-linking of DNA
strands by chloroethylation of DNA at a nucleophilic site on one DNA strand and
displacement of a chloride ion on the other strand [9] [10]. Chloroethylation produces
ethyl bridges between these two DNA strands. This cross-linking causes the disruption
of DNA unwinding that ultimately hinders synthesis of DNA and RNA.
Intravenous perfusion (IV) or oral administration are the traditional methods of
delivering BCNU to the tumor site. The action of BCNU against gliomas is shown
to be dose-dependent, with higher exposure resulting in decreased tumor growth in a
rodent model of GBM [11]. Systemic delivery of BCNU has prolonged the survival of
GBM patients but not without significant drawbacks such as debilitating side-effects,
insufficient drug exposure due to the short half-life of BCNU, and unsatisfactory drug
distribution throughout the brain[8].
Common side-effects caused by systemic administration of BCNU include hematopoi-
etic depression, nausea and vomiting, acute leukemia, damaging cytotoxic effects on
the kidney, liver, lungs, and central nervous system, and short drug exposure time
to tumor tissue [10]. Life-threatening adverse events include severe brain edema and
seizures[12]. The necessity of frequent repeat clinical visits for IV perfusion also
makes systemic delivery of BCNU unattractive to patients. Studies have shown that
BCNU tumor penetration and radial drug distribution are very low (2 mm) when
delivered systemically [8]. Novel delivery methods to overcome toxic BCNU-induced
side-effects and increase drug exposure to the tumor bed will be discussed in the
following section.
Temozolomide
Temozolomide (TMZ) [13] is the current standard chemotherapeutic drug used for
the treatment of GBM. The development of TMZ dates back to the early 1980s when
the drug was first synthesized by scientists at Aston University. Temozolomide is
categorized as a pro-drug due to the fact that its hydrolyzed product, MTIC, is the
biologically active component of the drug. Once formed from TMZ, MTIC rapidly
breaks down to form the highly reactive methyldiazonium ion [9]. The decomposi-
tion/hydrolysis mechanisms for TMZ are shown in Figure 1-2.
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Figure 1-2: Temozolomide decomposition pathways
[14]
The production of MTIC from TMZ in aqueous solution is highly dependent on
the pH of the environment. Temozolomide is stable under acidic conditions, but the
rate of degradation increases as the pH becomes more basic. In phosphate buffer at
pH 7.4, the half-life of TMZ is 1.24h [14]. The MTIC molecule exhibits pH-dependent
stability opposite to that of TMZ. MTIC is stable at basic pH and rapidly degrades
in acidic environments.
The stability of TMZ in acidic conditions allows it to be administered orally
because the TMZ molecule is able to withstand the high acidity of the stomach.
After leaving the systemic circulation and passing through the blood brain barrier
(BBB), the pH of the surrounding environment changes. Brain tumors have a more
alkaline pH than normal brain tissue [14]. This change in pH suggests that once TMZ
reaches the intracranial tumor mass, pH-mediated decomposition of TMZ results in
the formation of cytotoxic MTIC molecules.
The primary antitumor effect caused by TMZ is methylation of tumoral DNA
[14]. The methylation process begins when the methyldiazonium ion formed from
MTIC gives its methyl group to the guanine molecules in GBM DNA. This results in
the formation of 06- and N-methylguanine. DNA methylation by methyldiazonium
also forms 0 6-methylguanine, which is the primary cytotoxic methylation event. The
formation of 0-methylguanine in the DNA leads to base mismatch between two DNA
strands. After DNA methylation by TMZ, DNA mismatch repair enzymes work to
remove the non-complementary bases, which in turn generates single and double-
strand breaks in the DNA helix. These breaks activate apoptotic pathways in the cell
cycle that eventually lead to cell death.
The approved chemotherapeutic schedule for TMZ is currently a daily dose of 150
to 200 mg/m 2 for 5 days of every 28-day cycle[15]. Clinical trials during the develop-
ment of TMZ lead to the discovery of its dose-limiting, toxic side-effects. When given
orally, the primary dose-limiting hematologic side-effects associated with TMZ are
leukopenia, seizure, thrombocytopenia, and myelosuppression [14]. Myelosuppression
and seizure are usually the most serious side-effects and are controlled by reducing
the TMZ dosing schedule or dosage. Non-hematologic side-effects include nausea,
vomiting, fatigue, constipation, and headache [9].
Doxorubicin Hydrochloride
Doxorubicin (DOX) is an anthracycline antibiotic with strong antitumor action against
lymphoblastic leukemias, sarcomas, lymphomas, mesotheliomas, carcinomas of the
head and neck, and cancers of the breast, pancreas, stomach, liver, ovary, lung, and
prostate [16]. Development of doxorubicin began in the 1950s when researchers began
to search for tumoricidal compounds produced by soil-based microbes. The doxoru-
bicin molecule is synthesized by the Streptomyces peucetius var. caesius fungus that
is found in Italy and is sometimes referred to as Adriamycin[17].
Doxorubicin causes cytotoxicity by intercalation within tumor cell DNA. The
chemical structure of DOX is depicted in Figure 1-3, and sheds light on the drug's
ability to disrupt the structure of cellular DNA helices [18]. The chemical structure
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Figure 1-3: Doxorubicin chemical structure
[18]
of doxorubicin is predominantly a planar anthracycline ring. This allows for facile
intercalation of doxorubicin into the DNA double helix and causes interference of
DNA polymerases [18]. Doxorubicin also disrupts the progression of the topoiso-
merase II enzyme, which unwinds DNA during transcription. These two mechanisms
both contribute to DNA, RNA, and protein synthesis inhibition and in turn arrest
cell proliferation during the S-phase of the cell cycle.
Doxorubicin is typically administered as an IV infusion of 40-75 mg/m 2 dose.
This dose is repeated at 3-4 week intervals until a cumulative dose of 450-550 mg/m 2
is reached. The risk of developing drug-related myocardial toxicity increases dra-
matically beyond this systemic dose. Congestive heart failure caused by doxorubicin
exposure is estimated to be as high as 20% in patients who receive cumulative doses
greater than 500 mg/m 2 . The prevalence of congestive heart failure severely limits
the usefulness of systemically-administered doxorubicin for treating GBM.
1.4 Barriers to Effective Chemotherapy
Extensive in vitro and in vivo studies have proven that BCNU, TMZ, and DOX
are all able to induce cytotoxic DNA damage to GBM cells. The administration of
chemotherapeutic molecules seldom results in long-term patient survival despite these
chemotherapeutic agents' cytotoxic abilities and only extends survival by months at
best. Low chemotherapeutic response rates are attributed to the presence of an
intact BBB, unsatisfactory drug chemical stability (short half-life), harsh systemic
side-effects (discussed earlier), development of genetic drug resistance mechanisms,
low drug distribution profiles, and small drug payloads to the brain. All of these
issues result in low tumor exposure to drug and contribute to unsatisfactory outcomes
associated with chemotherapy. The goal of this thesis is to develop a drug delivery
microcapsule that is capable of addressing each of these limitations in a clinically-
relevant design.
1.4.1 Blood Brain Barrier (BBB)
The BBB is located at the capillary endothelium level of the brain, and its primary
function is to act as a molecular filter that separates the systemically circulating blood
from cerebrospinal fluid. The BBB is composed of tight junctions between capillary
endothelial cells, membrane pumps, and the endothelial basal membrane[4]. These
tight junctions restrict the diffusion of large, hydrophilic molecules while allowing the
diffusion of small, hydrophobic (or lipophilic) molecules such as 02. Harmful materials
such as bacteria are actively blocked by the BBB, but the passage of nutrients and
other small molecules that are necessary for brain cell survival is allowed.
The TMZ molecule is lipophilic and small, with a molecular weight of 194.151
daltons[19]. These two properties enable TMZ to pass through the blood-brain-barrier
(BBB) very effectively after oral administration of the drug [9]. The effectiveness of
oral TMZ treatment is confirmed by its high bioavailability to the CNS (20-40% of
plasma exposure) [9] [19]. BCNU is also relatively small and lipophilic[11] and has
a molecular weight of 214.049 daltons. It has been hypothesized that the passage of
BCNU through the BBB is allowed primarily due to its small molecular structure and
interaction with cell transmembrane proteins.
The therapeutic potential of DOX is hindered greatly by the BBB when the drug is
administered systemically. The doxorubicin molecule has a molecular weight of 532.52
daltons, and is much larger than both TMZ and BCNU. Unlike TMZ, DOX is non-
lipophilic and has a lower bioavailability. Its non-lipophilic structure and relatively
large molecular size restrict DOX from easily crossing the BBB. This results in a need
for high systemic doses and increases the incidence of harsh side-effects that occur
before the drug is even able to reach therapeutic levels in the brain tissue.
1.4.2 Drug Stability
The chemical stability of chemotherapeutic agents is important from an experimental
and clinical point of view. Accurate knowledge of the half-lives of these drugs in
biological fluids facilitates the task of formulation during pre-clinical development
and enables prediction of clinical efficacy prior to in vitro cell studies. Developmental
drugs with extremely short half-lives may lack clinical relevance because they degrade
long before the drug is able to reach the tumor site. Drug stability can be increased by
protecting the chemotherapeutic agent from the surrounding environment. Doxil@,
a liposomal formulation of DOX, and Gliadel@, a polymer-BCNU composite, are
two novel technologies that work to address the issue of chemical stability. Both
formulations will be discussed in the following sections.
1.4.3 Drug Distribution and Payload
Even if chemotherapeutic agents are able to cross the BBB and are stable enough
to reach the primary tumor site, malignant gliomas are known to penetrate and in-
vade brain tissue surrounding the main tumor mass. These migratory cells commonly
appear 2 to 3 cm away from the parent tumor and are the main cause of progres-
sion of primary GBM cells and recurrence after surgical resection [6]. Conventional
chemotherapeutic treatment strategies (IV and oral) have been insufficient to achieve
the necessary drug payload needed to target migratory cells. Better techniques are
urgently needed.
Localized drug delivery and convection enhanced drug delivery (CED) are two
state-of-the-art methods that have been developed to enhance drug exposure time,
payload, and distribution. Chemotherapeutic agents are conventionally administered
directly to the tumor site by devices implanted near the tumor bed. CED is an-
other form of local delivery that is achieved by infusion of drug solution through an
implantable catheter that is attached to an external drug reservoir. Localized drug
delivery methods are able to deliver high payloads of drug with long exposure times
directly to the tumor bed but suffer from limited drug distribution. CED can the-
oretically achieve higher drug distribution than local delivery but also suffers from
unpredictable fluid partitioning in the brain, tissue damage caused by high infusion
pressures (up to 70mmHg) [20], and increased incidence of intracranial infection. A
theoretical graph showing the qualitative contrast in drug distribution between these
two methods along with the advantages and disadvantages of both is presented in
Figure 1-4. The development of drug delivery devices that are capable of exploiting
the positive aspects of these two methods is an exciting treatment modality for GBM
therapy that will be addressed in this work.
1.5 Novel Chemotherapeutic Delivery Methods
The problems associated with chemotherapeutic treatment of GBM can be addressed
by developing new methods of drug delivery. Local intracranial administration of
chemotherapy directly to the tumor mass circumvents the BBB and decreases side-
effects caused by systemic drug infusion. Innovative techniques for localized drug
delivery can also introduce high dose chemotherapy with controllable drug distribu-
tion profiles to malignant glioma. Encapsulation of drug using polymeric materials
shields the drug from the outside environment and increases drug stability and blood
circulation times in vivo. Experimental research has produced clinically-relevant,
FDA-approved drug formulations and devices that directly address these issues. The
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devices and formulations important to this thesis will be discussed within the context
of the previously selected chemotherapeutic drugs.
1.5.1 Enhancing Carmustine Delivery (Gliadel® Wafer)
One of the most important revolutions in brain cancer therapy has been the develop-
ment of localized delivery of BCNU directly to the GBM tumor bed. Initial research
into the use of drug-impregnated polymer systems as a method to achieve localized
drug delivery following surgical resection led to the successful development and FDA
approval of the Gliadel® wafer in 1996 [12]. The Gliadel@ approach allows for con-
tinuous delivery of BCNU from a poly[bis(p-carboxyphenoxy)] propane-sebacic acid]
p(CPP:SA) copolymer matrix [22]. Gliadel@ devices measure 1.45 cm by 1mm, and
the geometry of the brain cavity limits the maximum number of implanted wafers to
eight [23]. The devices are implanted around the tumor bed after debulking surgery,
and therapy is supplemented with postoperative radiation. The p(CPP:SA) polymer
matrix hydrolyzes over time into non-toxic soluble monomers that are then metabo-
lized by the body as BCNU is released from the device.
Gliadel® drug delivery devices address the issues of low drug stability and low
drug exposure times to tumor. The half-life of systemically-administered BCNU is
12 minutes, and research has proven that BCNU delivered from the Gliadel® wafer
achieved drug concentrations that were log orders higher than the systemic dose,
suggesting that the p(CPP:SA) polymer matrix protected BCNU from degradation
[22]. BCNU is released over a period of 2-3 weeks when delivered using the Gliadel@
wafer, a significantly longer exposure time than that of systemically administered
BCNU [22]. The ability of this technology to overcome some of the limitations of
conventional chemotherapy along with its proven clinical efficacy made Gliadel@ the
first new treatment approved for brain tumor therapy in over 20 years [12].
The Gliadel® wafer drug delivery system is not without its share of limitations.
The wafers are thin and fragile, and anecdotal evidence notes that surgical implan-
tation of the wafers is extremely difficult to perform without breaking the devices.
Broken wafers contribute to increased intracranial edema and a potentially toxic
"burst" release of chemotherapy. The unpredictable drug release rates associated
with broken wafers has a detrimental effect on patient QOL and can lead to fatal
clinical complications.
The total drug payload offered by Gliadel@ is also cause for concern. A single
wafer contains only 3.85% BCNU by weight, and assuming that the maximum number
of wafers are implanted, the total dosage is near 62 mg of BCNU[24]. A typical
surgical debulking session will be unable to remove enough tissue to house eight
Gliadel® wafers in the resection site, further reducing the total drug payload. It is
interesting to note that during development of Gliadel@, higher doses were found to
be efficacious in animal models, but a much lower dose of 3.85% was used in humans
without extensive investigation into dose escalation experiments. A 20% BCNU-
loaded wafer (the confirmed maximum tolerated dose in humans) with experimentally
proven efficacy is now undergoing clinical trials in humans[12], but one has to question
why these experiments were not performed before FDA approval of the 3.85% wafer
was granted.
1.5.2 Enhancing Doxorubicin Hydrochloride Delivery (Doxil®)
A liposomal IV formulation of doxorubicin was developed in an effort to both de-
crease the detrimental myocardial toxicity associated with the drug and to increase its
blood circulation time. This formulation, Doxil®, consists of doxorubicin hydrochlo-
ride encapsulated in a liposome sphere that is composed of hydrogenated soybean
phosphatidylcholine, cholesterol, distearoylphosphatidylethanolamine, and a surface-
coating of polyethylene glycol (PEG) [25]. Each of the components in this novel drug
delivery system carry out specific functions, all of which contribute to the higher
efficacy found with Doxil® when compared to free doxorubicin.
The doxorubicin molecule in the Doxil® formulation is no longer used in its free-
base form but is formulated with a hydrochloride salt. This formulation greatly
increases the solubility of doxorubicin and leads to higher drug loading into the li-
posome aqueous space. The presence of the liposomal layer shields the encapsulated
doxorubicin from the surrounding environment and may increase drug stability. The
final component, the surrounding PEG layer, increases blood circulation time by at-
tracting water molecules that shield the liposomes from detection and destruction by
the immune system.
Doxil@ has been used as an experimental chemotherapy for convection enhanced
drug delivery. U-251MG and U-87MG brain tumor cell lines were implanted intracra-
nially in nude rats prior to Doxil@ administration. Results showed that intracranial
convection-enhanced delivery of DOX resulted in wider drug distribution than free
DOX and decreased tissue damage at the infusion site. Liposomal encapsulation of
DOX also allowed for long-term sustained drug release that was not observed in the
free DOX group. Statistically significant prolongation of survival was present in both
glioma xenograft groups[261.
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Chapter 2
Device Concept and Engineering
The main problems associated with systemic chemotherapeutic delivery were dis-
cussed in the previous chapter, and include debilitating side-effects, poor patient
QOL, non-efficacious drug exposure time, insufficient total drug payload, and only
modest increases in patient survival. Oral systemic delivery of TMZ requires large
systemic doses and produces unacceptable side-effects without curative outcomes. Lo-
calized drug delivery through the use of implantable devices such as Gliadel@ offers a
number of advantages over systemic drug delivery methods, but also suffers from its
own set of drawbacks. Drug distribution and payload delivered by Gliadel@ wafers
is too low, the devices are extremely large and fragile, and the use of Gliadel@ in
recurrent GBM patients has not shown a statistically significant benefit in survival
between patients receiving Gliadel@ versus placebo [27].
CED has been studied as an alternative to local implantation of drug delivery
devices. The catheterization necessary for convection enhanced delivery of Doxil@
greatly increases the risk of intracranial infection. Issues associated with catheter
blockage by tissue and drug partioning in the brain further limit the effectiveness
of convection enhanced delivery[20]. A phase III randomized clinical trial found no
significant difference in patient survival between Gliadel@ and CED of cintredekin
besudotox[20].
The device presented in this thesis aims to address the disadvantages of con-
ventional drug delivery by development of an implantable, biodegradable, controlled
release, polymeric microcapsule that delivers either TMZ or DOX following implanta-
tion into the brain. It is hypothesized that device implantation around the periphery
of the tumor bed may be able to achieve both high local drug concentrations and
drug distribution profiles that rival CED. The microcapsules are implanted following
surgical tumor resection. Diffusion-controlled release allows for tunable drug delivery
kinetics that are manipulated through changes in the number and diameter of orifices
in the microcapsule device.
2.1 Diffusion-Controlled Devices
The release of drug from microcapsules by diffusion requires establishment of a con-
centration gradient between the inside of the device (where drug is stored) and the
surrounding environment. According to the second law of thermodynamics, in or-
der to maximize entropy this gradient must induce migration of drug from areas of
high drug concentration (inside the microcapsule reservoir) to areas of low drug con-
centration (the surrounding brain tissue) [28]. This phenomenon can be expressed
mathematically through the use of Fick's First Law of Diffusion.
The flux, or rate of change of a solute across a boundary is defined as,
d (Q)
A =(2.1)dt
where J is the material flux, measured in -i. "A" represents the cross-sectional area
of diffusion. Q represents the amount of material (drug) that flows through or across
A. The amount of material that crosses A over a time interval, At is given by,
AQ = AJAt (2.2)
Fick's First Law of Diffusion relates the flux of material across a boundary to the
concentration gradient, and is defined as,
ac
J = -D O(2.3)Ox
where D is the diffusion coefficient of the drug, measured in -i-, and is the con-
centration gradient. Experimental studies approximate the diffusion coefficient, D, of
small molecules in solution as 10- M[281.
Fick's First Law of Diffusion assumes a linear, steady-state change in drug concen-
tration that does not depend on time. We use this approximation in our experiments
by assuming that drug in the capsule reservoir is completely saturated, and the fluid
surrounding the device is at "infinite sink" conditions at all times. We also assumed
uni-directional drug diffusion for simplification. These approximations change the
differential expression to the following form,
c = -D (2.4)
where Ac is the concentration of the drug outside the device reservoir less the solu-
bility of drug inside the device, and Ax is the length over which the drug diffuses.
Multiplication of the flux, J, by the cross-sectional area for diffusion, A, gives the
drug release rate from microcapsule devices, measured in 1. The application of Fick's
First Law of Diffusion to tailor the drug release kinetics of our microcapsules through
changes in orifice number and diameter will be discussed in the following chapter.
2.2 Chemotherapeutic Drug Selection: Temozolo-
mide and Doxorubicin Hydrochloride
2.2.1 Temozolomide
TMZ is the current state-of-the-art chemotherapetic agent for systemic treatment of
GBM, and was the first molecule chosen for release from the microcapsule devices de-
veloped in this thesis. The chemical properties, structure, and mechanism of action
for this drug were presented in the previous chapter. The oral formulation of TMZ,
Temodar@, was initially developed out of the need for more potent chemotherapeutics
with better activity against GBM than BCNU. Temodar@ is available in six different
doses which range from 5 mg to 250 mg[29]. This oral formulation contains drug
excipients and preservatives in addition to TMZ powder. Temodar@! exhibits mod-
est side-effects, higher bioavailability, and increased penetration through the BBB
when compared with systemically administered BCNU. It has subsequently displaced
BCNU as the standard in chemotherapeutic treatment of GBM.
It has been hypothesized that local delivery of TMZ may dramatically increase its
effectiveness against GBM, much in the same way that research into localized BCNU
therapy lead to FDA-approval of Gliadel@. Our research collaborators at Johns
Hopkins University were the first to demonstrate that local delivery of TMZ from
polymer-impregnated wafers was efficacious and superior to oral TMZ administration
in a rodent model of GBM [30]. The TMZ-polymer composite wafers developed by
the Hopkins group use the same polymer matrix as the Gliadel® system and have a
maximum drug payload of 5mg TMZ. The small drug payload and non-tunable drug
release kinetics of the wafer approach have led to the microcapsules developed in this
thesis. In vitro and in vivo experiments were conducted to compare the efficacy of
TMZ delivery from our microcapsule delivery system against oral Temodar@ and the
Hopkins TMZ-polymer composite wafers.
2.2.2 Dose Escalation
We hypothesized that one of the main reasons for the failure of chemotherapeutic
treatment of GBM is due to insufficient drug payload delivery to the tumor site.
Systemic-to-localized delivery dose escalation calculations were performed in order
to examine the feasibility of delivering the entire oral TMZ treatment regimen from
locally-implanted polymer wafers and micro-capsule devices. These calculations are
detailed below.
A phase III clinical trial published in the New England Journal of Medicine found
the following TMZ dosing schedule to be efficacious in GBM patients: 75mg/m 2/day,
given 7 days/week for 7 weeks. After a 4-week break, patients were given 150mg/m 2/day
for 5 days every 28 days. The final dosage was 200mg/m 2/day for 5 days every 28
days[15]. This final regimen was repeated up to 5 times. This schedule was used for
the systemic-to-localized delivery dose escalation calculations in this thesis.
In order to calculate the final required human TMZ oral dose, a few assumptions
must be made. In this present work, an average weight of 86.6 kg was used for human
male dose escalation, and an average weight of 74.4 kg was used for a human female.
A body-to-mass index (BMI) of 22 1 was used for both males and females[31]. The
resulting body surface area (BSA) values are given by the following equations,
Human Male: 22 kg x = 3.93636 m 2  (2.5)
m2  86.6kg
Human Female: 22 kg x 1 3.38182 m 2  (2.6)
m 2  74.4kg
where BSA values are subsequently used for calculation of the required systemic TMZ
doses in males and females.
The total systemic TMZ payload for a human male is given by the equations,
a. 75 2 x 3.93636 m 2 x 7 days = 2.07 9 x 7 weeks = 14.5g (2.7)
m2 x day week
b. 150 mg X 3.93636 m 2 = 590.545 mg x 5 days = 2.95g (2.8)
m x day day
c. 200 mg x 3.93636 m 2  787.272 mg x 25 days = 19.7g (2.9)
m x day day
where (a.) represents the initial dose of 75mg/m 2/day, given 7 days/week for 7 weeks,
(b.) represents the second dose of 150mg/m 2/day for 5 days every 28 days, and (c.)
represents the third schedule of 200mg/m 2 /day for 5 days every 28 days. Summation
of equations (1.3)-(1.5) gives a total male systemic TMZ dose of 37.15g. Similar
calculations give a total female systemic TMZ dose of 31.88g.
The total, 8 month systemic TMZ dose offers a starting point for calculating
the total dose needed for delivery from locally-implanted devices. Polymer drug
delivery wafers and microcapsules provide localized delivery of TMZ that bypasses
systemic metabolism and the BBB. The bioavailability and BBB-partitioning of TMZ
are assumed to be nearly 100% and 35%, respectivelyf[32] [33]. A 100% bioavailability
suggests that the entire oral drug payload reaches the systemic circulation, and a
35% BBB-partitioning value assumes that 35% of the circulating drug reaches the
cerebrospinal fluid (CSF). Pharmacokinetic models and experiments have confirmed
these values. Usage of the assumed systemic bioavailability and BBB-partitioning
values allows calculation of the total required local TMZ dose by the equations,
Human Male: 37.15g x 0.35 = 13g (2.10)
Human Female: 31.88g x 0.35 = 11.16g (2.11)
where a total of 13g TMZ for males and 11.16g TMZ for females needs to be delivered
locally from polymer wafers and microcapsules.
The polymer wafers developed at Johns Hopkins University can deliver a maxi-
mum TMZ payload of 5mg, and the microcapsule system can deliver up to 12mg of
TMZ. 2600 wafers or 1084 micro-capsules would need to be implanted in order to
achieve the required 13g payload in a human male brain. Implantation of this num-
ber of devices is not surgically feasible, but despite this shortcoming, local delivery
of TMZ offers an important starting point for improving drug delivery to GBM by
demonstrating that local delivery extends the survival of tumor-challenged animals
more so than conventional oral delivery. It may also not be necessary to deliver the
entire, 8 month course of chemotherapy locally, and the microcapsule system could
be used as an adjuvant therapy along with oral TMZ and radiation. This would
substantially reduce the number of implanted devices. The need for more potent
chemotherapeutic molecules with substantially lowered doses, such as doxorubicin
hydrochloride, led to the selection of DOX as the second model chemotherapeutic for
delivery from microcapsule devices.
2.2.3 Doxorubicin Hydrochloride
Recent clinical studies of intratumoral infusion of 5mg DOX over ten days were shown
to increase patients' time to disease progression by 36±2 weeks, and the median
survival of all ten patients enrolled in the study was 36.2±22.4 weeks [34]. Localized
delivery of DOX also resulted in no significant adverse side-effects[34]. This method
offers a way to decrease the development of cardiac toxicity caused by systemic DOX
infusion. The DOX dosage used in this study is substantially lower than the currently
prescribed TMZ dose.
The microcapsules fabricated in this thesis can theoretically be loaded with a
much larger payload (20 mg) than used in the Voulgaris study and can also be tuned
to release this payload directly to the tumor site over a chosen amount of time.
Delivery of DOX from microcapsule devices may allow for administration of the entire
drug therapy from one device instead of the thousands needed for satisfactory TMZ
delivery. The extremely low BBB-partitioning of DOX along with its high systemic
toxicity and low local dosage requirements make it an attractive molecule for localized
drug delivery from our microcapsules.
2.3 Material Selection: Poly-L-Lactic Acid and Liq-
uid Crystal Polymer
Development of any implantable device requires careful selection of suitable materi-
als for its construction. The material should meet the following criteria: 1) Must be
biocompatible. 2) Must provide a hermetic barrier that prevents unpredictable drug
leakage. 3) Must protect the drug from degradation by the surrounding environ-
ment. 4) Must maintain mechanical and structural integrity throughout the entire
course of drug therapy. 5) Must degrade into non-toxic, biocompatible monomers
after completion of drug delivery, if the material is biodegradable. 6) Must allow for
easy manufacture with precise dimensional tolerances through the use of standard
industrial techniques (injection molding, extrusion, etc). The two materials chosen
for fabrication of the micro-capsules in this thesis were liquid crystal polymer (LCP),
and poly-L-lactic acid (PLLA).
2.3.1 Poly-L-Lactic Acid
Poly(esters) are the best characterized and most widely studied biodegradable poly-
mer system[35]. Poly(lactic acid) (PLA) belongs to this class of polymers, and was
one of the first polyesters used for biomedical applications when a patent for its use as
a resorbable suture was filed in 1967. Other popular biocompatible polyesters include
poly(lactic-co-glycolic) (PLGA) and PLLA. Polyesters have also been extensively used
in drug delivery applications. A polymeric drug delivery device developed by Grayson
et al, produced resorbable millimeter size devices made of compression-molded PLLA
reservoirs with thin PLGA membranes. These devices showed non-toxic in vivo degra-
dation, and efficacious delivery of BCNU to a rodent glioma model[11] [36].
Lactide monomers are formed by dimerization of lactic acid molecules. These lac-
tide monomers are then synthesized into PLLA through ring-opening polymerization.
The polymerization mechanism is shown in Figure 2-1. Ring-opening polymerization
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Figure 2-1: Ring-opening polymerization of lactide.
[37]
of the cyclic lactide monomer is usually too slow to produce high molecular weight
polymer. The rate of polymerization is commonly increased by adding a catalyst
such as stannous octoate to the monomer mixture[35]. Stannous octoate is a bio-
compatible, FDA-approved food stabilizer that has proven safe for use as a polymer-
ization catalyst. Tin(II) 2-ethylhexanoate has also been used as a catalyst in PLLA
polymerization [37].
Naturally occurring lactic acid contains an asymmetic a-carbon that is described
as the D or L form, in stereochemical terms. PLA contains a mixture of L and D
forms, while PLLA is a homopolymer of the L form. The difference in stereochemistry
between PLA and PLLA has direct effects on the physical properties of the two
polymers. For example, the melting temperature of crystalline PLLA is 170 0C and
PLA is completely amorphous, with no observable melting point [35].
PLLA is considered more biocompatible than PLA and PDLA because the L-form
is naturally occurring. The PLLA polymer is derived from monomers that are natu-
ral metabolites of the body. After degradation of PLLA, the resulting hydroxy acid
monomers are readily absorbed by the body. The degradation of PLLA occurs primar-
ily through bulk degradation with hydrolytic scission of the polymer backbone[35].
The degradation rates of the PLLA used in our microcapsule devices depend on de-
vice geometry and thickness, injection molding process conditions, and the resulting
crystallinity of the polymer. The PLLA purchased from Lakeshore Biomaterials that
is used in this work has a degradation timeframe of greater than 24 months. The mi-
crocapsule devices are engineered to release the entire drug payload after a maximum
of two weeks, meaning that the polymer housing will fully degrade months after drug
therapy is complete.
2.3.2 Liquid Crystal Polymer
Previous experimental studies in our laboratory found that PLLA drug delivery de-
vices loaded with carmustine failed to pervent partitioning of drug through the poly-
mer housing. This led to unsatisfactory drug release profiles and unacceptable drug
leakage. The hermeticity of these devices was compromised, which resulted in the
need to re-evaluate the material choices for use in the current microcapsule delivery
devices.
Liquid crystal polymers (LCP) are a unique class of polymers that exhibit liquid
crystal phase characteristics either in solution or in the melt. A substance's liq-
uid crystalline state is defined by the one- or two-dimensional long-range molecular
order that is maintained above the material's crystalline melting point[38]. Liquid
crystalline behavior in polymer systems is due mainly to molecular rigidity of the
polymer chains that excludes more than one molecule from occupying a certain vol-
ume. Molecular shape anisotropy is the main requirement for a polymer to show
liquid crystalline behavior.
The molecular arrangement of polymer chains in the liquid crystalline phase is
directly related to the polymer's physical behavior and properties. Liquid crystal
polymer melts have lower viscosities than melts of random-coil polymers because the
liquid crystal polymer chains are able to align with the direction of flow. Industrial
processing of low-viscosity liquid crystal materials is much easier than with random-
coil polymers. The extension and orientation of polymer chains during processing also
yields highly crystalline solid polymers with extremely high modulus and strength
values.
The barrier properties of LCP make it an attractive alternative material to PLLA
for use in the fabrication of drug delivery devices. LCP polymers exhibit very low
moisture absorption ( 0.02%) and have low moisture permeability[39]. LCP also has
excellent chemical resistance to most acids, bases, and solvents[39], and has been used
in moisture-resistant medical packaging products[40]. The strong barrier properties
and great chemical resistance of LCP suggest that micro-capsules fabricated from this
material may be able to successfully store the drugs used in this current work. Exper-
imental drug leak tests were performed in order to test the reliability and hermeticity
of LCP polymer microcapsules.
Unlike PLLA, LCP polymers are not biodegradable. Despite this, the LCP used
for the devices presented in this thesis (Vectra MT1300) is bioinert, and has passed the
USP (United States Pharmacopeia) class VI biocompatibility test. This test consists
of intracutaneous injection, systemic LCP injection, and implantation tests. The in
vivo compatibility of LCP with rodent brain tissue was qualitatively assessed in this
thesis by checking for the presence of fibrous tissue growth around the microcapsule
and measuring animal survival times when implanted with unloaded microcapsules.
The results of these experiments are presented in the results chapter.
2.4 Tumor Model Selection: 9L Gliosarcoma
The selection of a clinically-relevant rodent tumor model is crucial to testing the
efficacy of drug delivery devices. There is no currently available animal tumor model
that is able to exactly simulate human GBM. A wealth of information has been
obtained from experimental animal GBM models. The use of animal models has led
to the development of new therapies and treatment strategies for human GBM. A
general consensus among researchers and clinicians states that valid GBM animal
models should be derived from glial cells, display glioma-like growth characteristics
within the brain, possess predictable and reproducible tumor growth rates, and their
response to therapy should closely simulate that of human brain tumors[41].
The 9L gliosarcoma xenograft model used in this work is one of the most widely
used of all rat brain tumor models. It can be grown both in vitro and in vivo which
makes it useful for a wide variety of studies ranging from in vitro drug resistance
experiments to in vivo intracranial pharmacokinetic studies[41]. The 9L gliosarcoma
is an attractive experimental model because it grows rapidly and unaltered Fischer
rats can be used for in vivo studies. This allows for quick experimental studies and
the use of inexpensive rodents.
The main problem associated with the use of the 9L xenograft cell line is its
non-invasive in vivo growth pattern[41]. Human glioma cell lines such as U87 and
SF-539 are able to invade the surrounding ECM; this growth is also commonly ob-
served in GBM patients. The use of human glioma in rodents requires the use of
immunocompromised, "nude" animals that are more expensive than Fischer rats and
are also more prone to opportunistic infections. U87 gliomas grow slower than 9L
gliosarcomas in vivo which results in much longer drug efficacy trials when survival
is the primary metric. The 9L model was chosen for use in this thesis as a relatively
quick target to assess efficacy of our drug delivery devices, and the U87 model will
be used in future long-term survival experiments.

Chapter 3
Microcapsule Design and
Manufacture
Two types of drug delivery microcapsules for treating GBM were developed in this
work. One device is fabricated from liquid crystal polymer (LCP), and the other
from a biodegradable polymer, poly(l-lactic) acid (PLLA). The design of both devices
includes a drug-storage reservoir and a cap used to seal the device from the outside
environment. Drug is released through circular orifices that are either molded or laser
drilled into each device. The rate of drug delivery is controlled by the diameter of
the orifice, the number of orifices, and the drug formulation. The inner volume of
the reservoir measures 15 pL, which allows for higher drug loading per device volume
when compared to previous polymer drug delivery devices[36] [30]. The higher drug
loading capability facilitates the local delivery of large drug payloads to tumors, which
is critical for effective chemotherapeutic treatments. These devices are engineered
using Fick's First Law of Diffusion to achieve desired release kinetics that fit the need
of disease treatment.
3.1 Design
3.1.1 Temozolomide-Releasing Devices
The SolidWorks 3D CAD software package was used to design the microcapsule de-
vices. The first-generation microcapsule devices designed to release TMZ allowed for
uni-directional drug delivery from a single 889 pm diameter orifice in the device cap
(Figure 3-la).
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Figure 3-1: Microcapsule device design. a) First Generation TMZ Device. b) Second
Generation TMZ Device. c) DOX Device
Results from the first TMZ in vivo efficacy study led to the hypothesis that multi-
directional drug delivery would increase the effectiveness of the microcapsules against
the 9L gliosarcoma model. This led to the fabrication of second-generation TMZ-
releasing microcapsules with a single 889 pin diameter orifice cap and four 403 p1m
diameter orifices around the circumference of the microcapsule reservoir (Figure 3-1b).
3.1.2 Doxorubicin Hydrochloride-Releasing Devices
Microcapsule devices for delivery of DOX were also designed using the SolidWorks
software package. DOX has a higher aqueous solubility than TMZ, which led to the
use of smaller orifice diameters in the DOX-releasing devices. The microcapsules used
for delivery of DOX have a single 180 pm diameter orifice in the device cap (Figure
3-1c). This smaller orifice allows for long-term controlled drug delivery over a period
of 2 weeks without a "burst" release of drug.
3.1.3 Microcapsule Device Fabrication
Metal mold cavities were fabricated based on the previously mentioned SolidWorks
designs. PLLA and LCP molten polymers were injection molded into their final micro-
capsule form at microPEP (East Providence, RI). The injection molding process
allows for high precision device production, giving reliable and consistent results,
including very small tolerances in payload volume and orifice diameter. The device
dimensions are shown in Table 3.1. The millimeter-scale dimensions were chosen to
allow for intracranial device implantation in Fischer 344 rats.
Reservoir Cap
Outer Diameter (mm) 3 2.97
Height (mm) 2.86 n/a
Outer (lip) Thickness (mm) n/a 0.09
Table 3.1: Microcapsule device dimensions
Injection molding is also capable of fabricating large numbers of devices in single
process runs. 180 pm diameter orifice devices were fabricated directly in the mold
cavity, while a drill press equipped with a #65 (0.0350 decimal equivalents) drill bit
was used to manufacture the 889 pm diameter orifice devices. An excimer laser system
(TeoSys Engineering LLC) operating at 193nm was used in order to manufacture the
four 403 pm diameter orifices around the circumference of the microcapsule reservoirs.
3.1.4 Drug Loading
A metal hopper was designed for use in loading chemotherapeutic drug into the
microcapsule reservoirs. An empty device reservoir was placed into the hopper mold
cavity, then a metal funnel was placed on top of the cavity. Precise amounts of solid
drug (12mg of TMZ or 1mg of DOX for in vivo experiments) were dispensed into
the funnel, and a tamping metal tool was used to compress the drug inside of the
microcapsule reservoir. Excess drug was cleared from the device reservoir by sliding
the funnel across the device and shearing the remaining drug.
3.2 Tailoring Drug Release Kinetics
The appropriate dimensions of the microcapsule orifice(s) and drug formulation de-
pend on the drug and treatment characteristics. The drug delivery devices developed
in this work were precisely tailored to function within the properties of the drug and
needs of the disease. Several pieces of information; drug solubility, drug stability and
the desired release rate, were critical to determining the final design of the devices.
Drug solubility and stability experiments will be presented in detail in the following
section. Fick's First Law of Diffusion was used to calculate the theoretical release
rate of drug from microcapsule devices.
3.2.1 Temozolomide-Releasing Microcapsules
Single-Hole Devices
The TMZ-impregnanted polymer wafers developed by Brem et al. were chosen for
comparison with our first generation microcapsule devices. An average release rate
of 1.17 mg per day from these wafers was shown to prolong rodent survival, and this
drug flux was used as a model delivery rate from the microcapsules. The theoretical
release rate of TMZ from single, 889 pm diameter orifice microcapsules was calculated
by using Fick's First Law of Diffusion,
J -D (3.1)JDAx
Ac -8.82 mg (3.2)
ml
Ax = 0.04cm (3.3)
C2
D = 10 -5  (3.4)
S
where Ac is equal to -8.82 '9 for TMZ, Ax is equal to 0.04 cm (the thickness of
the device cap), and D equals 10 ' m. Multiplication of these terms gives the flux,
J, as 2.205 x 10-3
The area of diffusion, A, is equal to the area of a circle,
A = -r 2  (3.5)
where, in the case of an 889 pm diameter orifice, A is equal to 6.207 x 10- 3cm 2 .
The release rate of TMZ can finally be calculated by multiplication of the flux, J,
by the area of diffusion, A,
Release Rate = J x A (3.6)
and the theoretical release rate of TMZ delivered from an 889 Pm diameter orifice
device is 1.4 x 10- Mg or 1.2096g. This theoretical release rate was used for compar-
ison with the experimentally determined TMZ release rates from the microcapsules.
Multiple-Hole Devices
Multiple orifice microcapsules were fabricated in order to increase the release rate
of TMZ. Four additional orifices were laser-drilled around the circumference of the
microcapsules to achieve multi-directional drug release. These second-generation mi-
crocapsule devices were manufactured with a total of five orifices for drug release:
One, 889 pim diameter orifice in the cap and four 403 pum diameter orifices around
the circumference of the microcapsule reservoir. The release rate of TMZ from these
devices was calculated using the same assumptions and approximations as in the
single-orifice case, and was found to be 2.5 x 10 "g, or 2.16g. The multiple-orifice
release rate is nearly twice as fast as the single-orifice release rate, and these devices
showed statistically significant increases in survival in an in vivo rodent 9L gliosar-
coma model.
3.2.2 Doxorubicin-Releasing Microcapsules
The literature values of DOX solubility ranged from 50 g to over 100 m, and the
amount of drug needed for experimental determination of solubility was financially
unjustifiable. DOX release rates were instead determined using the previously manu-
factured microcapsule devices. Initial in vitro drug release studies showed that DOX
release from a single 889 pm diameter orifice device resulted in an unsatisfactory
"burst" release of drug over one hour. This type of release is extremely dangerous be-
cause the large release of a potent drug over a short time period can cause local tissue
necrosis and debilitating side effects. A single 180 pm diameter orifice microcapsule
was used for delivery of DOX, and was tested in vitro and in vivo.
Chapter 4
Materials and Methods
4.1 Materials
Temozolomide (TMZ) was provided by the National Cancer Institute (NCI, Bethesda,
MD). HPLC-grade water, ammonium acetate, acetonitrile, hydrochlorothiazide, and
doxorubicin hydrochloride (DOX) were purchased from Sigma-Aldrich. Phosphate
buffered saline (PBS), fetal bovine serum (FBS), and pH buffers were purchased from
VWR International.
4.2 Device Fabrication
Liquid crystal polymer, LCP, (Vectra MT1300) was purchased from microPEP (East
Providence, RI). Poly(l-lactic) acid, PLLA, (100 L) was purchased from Lakeshore
Biomaterials (Birmingham, AL). PLLA and LCP polymer microcapsule devices were
injection molded into their final form at microPEP (East Providence, RI).
4.3 Temozolomide Characterization
4.3.1 High Pressure Liquid Chromatography
Two methods were used to quantify TMZ using high pressure liquid chromatography
(HPLC). The first method was employed for samples of TMZ in HPLC-grade water,
PBS, and pH buffers. 20 pL of sample was quantified at 37 C on an Agilent 1200
Series HPLC using a Synchropak SCD-100, 5 pum, 150x4.6 mm column (Synchrom,
Lafayette, IN, USA), a flow-rate of 0.4 ml/min, 0.01 M ammonium acetate (aque-
ous):acetonitrile (92:8) mobile phase, and UV absorption at 316 nm. The results
from this method were used to construct a standard curve for use in quantification of
in vitro TMZ release from polymer microcapsule devices.
A second method was used for quantification of TMZ in FBS. The same chromato-
graphic conditions were used with the addition of sample clean-up and preparation
steps. 200 pL of TMZ sample was added to 100 pL of 100pg/mL hydrochlorothiazide.
The resulting solution was vortexed and then spun at 4500 G using a MiniSpin cen-
trifuge (Eppendorf) at room temperature for 1 minute. Samples of the supernatant
were analyzed on the HPLC (these methods were adapted from Kim et al) [42].
4.3.2 Temozolomide Stability
Drug stability studies were conducted in HPLC-grade water, PBS, and FBS. Approx-
imately 1 mg of TMZ was added to 2 mL of solvent. The resulting solutions were
stored at 37 C and sampled periodically over a 14 hour time period. Samples were
analyzed for TMZ content by the HPLC methods described above. Quantification
of the internal standard hydochlorothiazide demonstrated that no appreciable losses
occurred due to FBS sample preparation.
4.3.3 Temozolomide Solubility
Saturated solutions of TMZ were prepared in pH 1, 2, 3, 4, and 5 buffers and in
pH 7 HPLC/MS grade water. Each buffer was analyzed using the HPLC method
described above to determine the presence of any interfering peaks. No interfering
peaks were found. Approximately 10 mg of TMZ were added to 500 pL of each buffer
solution at 37 C. Each solution was left for 20 minutes at 37 C with intermittent
vortexing. Solutions were then spun at 10,000rpm for 5 minutes using a MiniSpin
centrifuge. Drug precipitate was present in all samples. Samples for HPLC analysis
were prepared from the supernatant at the following dilutions; pure supernatant, 1:5,
1:10, and 1:20. All dilutions were made with the appropriate buffer pre-heated to
37 0C. Samples that read in the linear range of the standard curve were used to
calculate solubility by adjusting the read concentration by the appropriate dilution
factor.
4.4 Doxorubicin Hydrochloride Characterization
4.4.1 Fluorescence Assay
The concentration of doxorubicin in HPLC-grade water was analyzed by fluorescence
assay. Measurements were made on a Synergy 4 fluorescence plate reader (BioTek
Instruments, Inc.) with a programmed internal temperature of 37 C. Intensity of
fluorescence emission was determined at 590nm with an excitation wavelength of
470nm [43]. Fluorimetric intensity readings were converted to mg/ml concentrations
by interpolation with the readings of a standard curve of doxorubicin in the linear
range.
4.5 In Vitro Drug Release Kinetics
4.5.1 Temozolomide-Polymer Composite Wafers
TMZ was incorporated into a polyanhydride CPP:SA polymer at a concentration of
50% (w/w) by methods described previously [44]. The polymers were then pressed
into a disc shape weighing approximately 10 mg. Total drug payload was approx-
imately 5mg per wafer. Wafers were placed into 2ml of HPLC/MS-grade water to
begin release studies. The sample bath was removed and refilled periodically for anal-
ysis of the drug concentration present in each sample. Samples were stored in liquid
nitrogen until analysis. Interpolation of the readings with a standard curve of TMZ
was used to quantify the amount of TMZ released over multiple days.
4.5.2 Temozolomide-loaded Drug Delivery Devices
Temozolomide was loaded into LCP single- and multiple-hole polymer microcapsules
for in vitro drug release characterization. Drug payload in each device was 12mg.
Single-hole devices had an orifice diameter of 889pm in the device cap. Multiple-hole
devices had a single 889pm-diameter cap orifice and four 403pm-diameter orifices
around the circumference of the device reservoir. After temozolomide was loaded into
each device, and caps were sealed to the reservoir with UV-curable epoxy (1-20542
UV Curing Cationic Epoxy, Dymax Corp, Torrington, CT). Devices were exposed to
UV light for a cure time of 90 seconds. Control devices with epoxy-sealed orifices
were fabricated for leak tests to examine the hermeticity of the UV epoxy and poly-
mer reservoir. A vacuum pump was used to remove residual air from the devices.
Devices were placed into 2ml of HPLC/MS-grade water to begin release studies. The
sample bath was removed and refilled periodically for analysis of the drug concentra-
tion present in each sample. Samples were stored in liquid nitrogen until analysis.
Interpolation of the readings with a standard curve of TMZ was used to quantify the
amount of TMZ released over multiple days.
4.5.3 Doxorubicin Hydrochloride-loaded Drug Delivery De-
vices
DOX was loaded into LCP single-hole drug delivery devices with a single 180pm
diameter orifice for in vitro characterization of release kinetics. Drug payload in
each device was 1mg. After DOX was loaded into each device, and device caps were
sealed to the reservoir with UV-curable epoxy (1-20542 UV Curing Cationic Epoxy,
Dymax Corp, Torrington, CT). Devices were exposed to UV light for a cure time of
90 seconds. Control devices with epoxy-sealed orifices were fabricated for leak tests
to examine the hermeticity of the UV epoxy and polymer reservoir. A vacuum pump
was used to remove residual air from the devices. Devices were placed into 2ml of
HPLC/MS-grade water to begin release studies. The sample bath was removed and
refilled periodically for analysis of the drug concentration present in each sample.
Samples were stored in liquid nitrogen until analysis. Fluorescence spectroscopy was
used to quantify the amount of DOX released over multiple days.
4.6 In Vitro 9L Gliosarcoma Cell Culture
MTT assay was used to quantify the effect of varying concentrations of DOX on
survival of 9L glioma cells cultured in vitro. Glioma cells were plated at a density
of 3500 cells/well, and DOX diluted in DMEM cell culture media with 10% glucose
(Invitrogen) was added to each well 24 hours after initial cell plating. DOX concen-
trations were: 50pg/ml, 10pg/ml, 5pug/ml, 1pg/ml, 0.5pg/ml, 0.1pg/ml, 0.05pig/ml,
0.01pg/ml, 0.005pg/ml, and control samples with blank growth media. Cells were
counted 48 hours following DOX administration in order to quantify the extent of
DOX-mediated cell death.
4.7 In Vivo Rodent Experiments
4.7.1 Tumor and Device Implantation
9L glioma cells were implanted in the flank of Fischer 344 (Harlan Sprague Dawley,
Indianapolis, IN) rats and allowed to proliferate for several weeks until a tumor of
approximately 2 cm diameter was grown. The tumor was harvested after euthanasia
of the rat and cut into pieces approximately 1 mm3 in volume. Female or male
Fischer 344 rats weighing 150-300 g were anesthesized with intraperitoneal injections
of a xylazine/ketamine stock solution, at a concentration of 3-5 ml/kg. The anesthesia
stock solution contained 25 mg/ml ketamine hydrochloride, 2.5 mg/ml xylazine, and
14.25% ethanol in 0.9% saline. The heads of anesthesized rats were shaved and
the skin prepped using a betadine scrub. A mid-line incision of 2-3 cm length was
made, followed by removal of the underlying membrane layer to leave a clear path for
drilling. A 3.5 mm diameter hole was drilled using a motorized power tip and attached
stainless steel drill bit. The hole was drilled 2-3 mm lateral to the midline suture and
5 mm posterior from the coronal suture, or 1 mm anterior to the interaural line.
A microscope was used to assist in implanting the tumor and drug delivery micro-
capsule, cap side down, into the intracranial space. Excess CSF fluid and white matter
were lightly suctioned to make space for the tumor and device. The skin of the head
was closed using autoclips once the implantation was completed, and animals were
returned to their cages.
4.7.2 Efficacy of Locally Delivered Temozolomide
Two experiments were conducted in order to determine the effectiveness of locally
delivered temozolomide in intracranial tumor-bearing Fischer 344 rodents. The first
pilot experiment included nine experimental groups: 1) Control animals with tumor.
2) Animals given oral temozolomide by gavage at a dose of 50mg/kg on days 5-9
after tumor implantation. 3) Animals given two 50%wt TMZ-polymer wafers. 4)
and 5) Control animals with tumor and blank LCP/PLLA microcapsules (no drug
payload). 6) and 7) Animals given TMZ-filled LCP/PLLA microcapsules on the day
of tumor implantation (Day 0). 8) and 9) Animals given TMZ-filled LCP/PLLA
microcapsules five days after tumor implantation (Day 5). All microcapsule devices
used in this experiment had a total TMZ payload of 12mg and single 889tm-diameter
orifice caps. The total number of animals used was 68. Overall animal survival was
compared to that of the device-free control group.
The results of the first in vivo efficacy experiment were used to design a second
in vivo experiment with modified drug delivery devices. This second study included
four experimental groups: 1) Control animals with tumor. 2) Control animals with
tumor and blank LCP microcapsules (no drug payload). 3) Animals given oral TMZ
by gavage at a dose of 50mg/kg on days 5-9 after tumor implantation. 4) Animals
given TMZ-filled LCP microcapsules on the day of tumor implantation (Day 0). All
drug delivery microcapsules used in this experiment had a total TMZ payload of 12
mg, single 889[m-diameter orifice caps, and four 403pm-diameter drug release orifices
around the reservoir of the device. The total number of animals used was 30. Overall
animal survival was compared to that of the control group.
4.7.3 Doxorubicin Hydrochloride Toxicity
DOX-loaded, single 889pm-diameter orifice microcapsules were fabricated for in vivo
drug toxicity studies. A drug payload of 1mg was loaded into each device. Three Fis-
cher 344 rats were used in this experiment. Animals were monitored for neurological
and behavioral changes throughout the study, including weight loss, failure to thrive,
and wound healing problems. Death was the primary endpoint of the experiment.
4.7.4 Animal Care
All animals were housed in standard facilities and given free access to food and water.
Rats were treated in accordance with the policies and guidelines of the Johns Hopkins
University Animal care and Use Committee. Each study was terminated at Day 120,
and the surviving rats were deemed long-term survivors (LTS). All excised brains
were stored in formalin following death prior to histological studies.
4.7.5 Statistical Analysis
Death was the primary endpoint for all in vivo efficacy studies. The method of Kaplan
and Meier was used to determine the distribution of intervals until death. Statistical
analysis (unpaired t-test) was performed using the Prism GraphPad software package.
4.8 Immunohistochemical Analysis
4.8.1 TUNEL Stain
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL staining)
was performed on rat brain tissue samples in order to quantify the ability of TMZ
to damage 9L glioma nuclear DNA. The protocol was specifically used for detection
and quantification of apoptosis at the cellular level. The TUNEL method works by
labeling DNA strand breaks that are caused by exposure to cytotoxic agents such as
TMZ. These single or double stranded breaks are identified by labeling the free 3'-
OH terminal with modified nucleotides[45]. Counting of cellular nuclei with TUNEL-
positive stains allows for quantitative determination of apoptosis. The rat brain tissue
used in this study was paraffin-embedded and sliced through the coronal plane before
TUNEL analysis. The multi-step staining protocol developed by Heatwole et al was
used [46].
Chapter 5
Results
5.1 Temozolomide Physical Chemistry
5.1.1 High Pressure Liquid Chromatography
A typical HPLC chromatograph of TMZ in water is shown. The retention time of
TMZ on the Synchropak SCD-100 column was 9.5 minutes when a flow rate of 0.4
ml/min was used. No interfering peaks were present throughout the HPLC analysis.
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Figure 5-1: TMZ HPLC Chromatograph
5.1.2 Temozolomide Stability
The chemical stability of TMZ was studied in water, PBS, and FBS. The data is
presented as normalized area-under-the-curve (AUC) values versus time, and was
collected over a period of fourteen hours. Exponential curve-fitting of the water,
PBS, and FBS data allowed for calculation of the half-life of TMZ in each of these
solvents. The results show that TMZ was most stable in water, with a half-life of 99
hours, followed by PBS and FBS, with half-lives of 5 and 0.7 hours, respectively. The
in vivo stability of TMZ calculated by Zhou et al is 0.9 hours[47], which is in close
agreement with our calculated value of 0.7 hours for TMZ in FBS.
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Figure 5-2: TMZ Stability
5.1.3 Temozolomide Solubility
Temozolomide solubility was assessed in pH 1, 2, 3, 4, and 5 buffer solutions and in
pH 7 water. Solubility values were calculated by comparing the AUC values obtained
using the HPLC system with values from a calibration curve of TMZ in the linear
range. These AUC values were then multiplied by the appropriate dilation factor used
in each study to produce the final solubility value. The resulting solubility values
showed a solubility range of 6.38 mg/ml for TMZ in pH 1 buffer to 11.5 mg/ml for
TMZ in pH 3 buffer. The solubility of TMZ in water was 8.82 mg/ml. A solubility
of 8.82 mg/ml was used in calculating the theoretical release kinetics for our drug
delivery devices because this solubility corresponds to the expected physiologic pH of
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Figure 5-3: TMZ Solubility
5.2 In Vitro Temozolomide Drug Release Kinetics
5.2.1 Polymer Wafers
The TMZ-impregnated polymer wafer device developed at Johns Hopkins University
served as a metric for comparison with our drug delivery microcapsules. The wafers
used in vitro and in vivo in this thesis had a total payload of 5mg TMZ per wafer.
The in vitro release of TMZ from these wafers into HPLC-grade water was assayed
by HPLC. The number of devices for each group in this experiment was three. Re-
sults were reported as average values with standard deviations for each time point.
Results showed that 75% of the total drug payload was released after 62 hours. This
corresponds to a TMZ mass of 3.75mg.
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Figure 5-4: Polymer wafer TMZ release into water
5.2.2 Single-Hole Devices
The in vitro release of TMZ from single 889 pum diameter orifice LCP drug delivery
microcapsules into HPLC-grade water was assayed by HPLC. Control devices with
completely sealed orifices were also fabricated in order to test the hermeticity of the
UV-curable epoxy. A theoretical release curve based on Fick's First Law of Diffusion
was constructed for comparison with experimental drug release data. The mass flow
rate calculated from Fick's 1st Law was 50.4 ug/hr. The number of devices for each
group in this experiment was three. Results were reported as average values with
standard deviations for each time point. The experimental release curves were in close
agreement with the theoretical release curve, especially at times before 80 hours. The
experimental TMZ release rate during the first 100 hours of release was 36 ug/hr.
At this time, 40% of the total 12mg was released. The release rate decreased after
100 hours, with a final drug release of 50% after 175 hours. The devices fabricated
for drug leak tests demonstrated that the UV-curable epoxy is capable of sealing
the devices and preventing leakage of drug from the devices. No drug partitioning
through the polymer housing was detected, suggesting that LCP is capable of storing
the drug throughout the length of therapy.
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Figure 5-5: Single-Hole TMZ release into water
5.2.3 Multiple-Hole Devices
LCP devices with multiple drug release orifices were tested in vitro to examine the
effect of increasing the number of release orifices on drug release rate. A theoretical
release curve based on Fick's First Law of Diffusion was constructed for comparison
with experimental drug release data. The mass flow rate calculated from Fick's 1st
Law was 90 ug/hr. The number of devices for each group in this experiment was
three. Results were reported as average values with standard deviations for each
time point. The experimental release curves were in excellent agreement with the
theoretical release curve. The experimental TMZ release rate during the first 100
hours of release was 88 ug/hr. At this time, 67% of the total 12mg was released.
The release rate decreased after 100 hours, with a final drug release of 71% after 190
hours.
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Figure 5-6: Multiple-Hole TMZ release into water
5.3 In Vivo Rodent Experiments
5.3.1 Fibrous Encapsulation
Fibrous encapsulation of foreign materials is a common response of the immune sys-
tem. This response is induced in order to sequester potentially harmful materials
from the rest of the body. The fibrous tissue commonly contains collagen, fibroblasts,
macrophages, and other cells of the immune system. Explanted microcapsule devices
were examined visually for fibrous capsule formation after animal death in all in vivo
experiments. No fibrous tissue was found. The reasons and implications for this lack
of fibrous tissue formation will be discussed in the following chapter.
5.3.2 Efficacy of Locally Delivered Temozolomide
Single-Hole Devices
In the initial in vivo rodent studies, the primary metric for drug delivery device
efficacy was animal survival. Animals that received 9L tumor (control animals) and
blank LCP microcapsules had the highest rate of death and a median survival of 11
days for animals given blank LCP microcapsules. Control animals and animals in
the blank PLLA device group died shortly after, with median survival times of 17
and 11 days, respectively. Rats given TMZ-loaded LCP and PLLA devices on day 5
after tumor implantation also showed high death rates and median respective survival
times of 17 and 18 days.
Rats from the oral TMZ, TMZ wafer, and day zero TMZ microcapsule groups
exhibited higher survival rates than the previously mentioned experimental groups.
Animals given oral TMZ by gavage had a median survival time of 24 days. Increased
rodent survival was achieved with the day zero TMZ-loaded LCP and PLLA groups,
with median survival times of 31 and 50 days, respectively. The highest animal
survival was found in the group that received two TMZ-impregnated polymer wafers
on day five of tumor implantation. Animals in this group had a median survival time
of 65 days.
Animals that survived 120 days or later were deemed long term survivors. There
were three experimental groups in this initial in vivo study that contained long term
survivors. These groups included 1) TMZ wafers, with four long term survivors. 2)
LCP-TMZ day zero, with three long term survivors. 3) PLLA-TMZ day zero, with
two long term survivors. No long term survivors were present in the group that
received oral TMZ treatment, the current standard of care.
Statistical analysis of the survival data was performed in order to quantify the
significance in animal survival between the control, oral, wafer, and LCP/PLLA
TMZ day zero groups. Statistically significant differences were observed between con-
trol/wafer (p<0.0001), control/LCP-TMZ day zero (p<0.0001), oral/wafer (p<0.0001),
and oral/LCP-TMZ day zero groups (p=0.0187). There was also statistical difference
between the wafer/LCP-TMZ day zero (p=0.015 4 ) and wafer/PLLA-TMZ day zero
groups (p=0.0004), suggesting that the wafer devices performed better in vivo than
the microcapsule devices. There was no statistically significant difference between
the day zero TMZ-filled LCP and PLLA devices.
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Figure 5-7: Localized TMZ Survival Experiment#1
Multiple-Hole Devices
The second in vivo TMZ experiment was performed in order to test the effectiveness
of multiple orifice LCP microcapsule devices implanted on the day of tumor admin-
istration. The results of this study for control, oral, and blank devices were similar
to the initial in vivo experiment. The median survival time for untreated control an-
imals was 14 days. Oral gavage animals had a median survival time of 26 days, and
day zero blank LCP animals had a median survival time of 13 days. Multiple orifice
LCP devices showed a median survival time of 62 days. This survival advantage was
two weeks greater than seen with single orifice LCP devices used in the first in vivo
experiment. 37.5% of these animals were long term survivors.
Statistical analysis of the survival data was performed in order to quantify the sig-
nificance in animal survival between the control, oral, and multiple hole LCP-TMZ
day zero groups. Statistically significant differences were observed between con-
trol/oral (p<0.0001), control/LCP-TMZ day zero (p<0.0001), and oral/LCP-TMZ
day zero groups (p=0.0005). The multiple-hole LCP devices have demonstrated im-
proved rodent survival rates when compared with single-hole microcapsules and the
current oral delivery standard of care.
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Figure 5-8: Localized TMZ Survival Experiment#2
5.4 In Vitro 9L Gliosarcoma Cell Culture
9L gliosarcoma cells were cultured in vitro and given varying concentrations of DOX
to assess the sensitivity of these cells to DOX. Results showed that a minimum DOX
concentration of 0.lug/ml was capable of decreasing cell survival by 80% after 48
hours incubation. Drug concentrations lower than 0.lug/ml showed varying amounts
of activity against 9L cells, but the effect was not as dramatic as higher DOX con-
centrations. This MTT assay proved that the glioma model used in this work was
sensitive to DOX.
5.5 In Vitro Doxorubicin Hydrochloride Drug Re-
lease Kinetics
A 1mg payload of DOX was loaded into single 180 pm diameter orifice LCP devices
for in vitro drug release characterization. Control devices for leak tests with a payload
of 1mg were also fabricated. The number of devices for each group in this experiment
was two. Results were reported as average values with standard deviations for each
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Figure 5-9: 9L-Doxorubicin MTT Assay
time point. The experimental DOX release rate during the first 100 hours of release
(the linear region) was 5.6 ug/hr. At this time, 50% of the total 1mng was released.
The release rate decreased after 100 hours, with a final drug release of 70% after 347
hours. Results from the drug leak experiments showed similar behavior as the TMZ
leak devices. No drug was detected in the release bath after 350 hours.
5.6 Doxorubicin Hydrochloride Toxicity
In vivo doxorubicin hydrochloride toxicity studies were performed in order to test the
feasibility of delivering the MTD local payload of 1mng DOX[16]. LCP microcapsule
devices loaded with 1mng DOX were implanted intracranially in three rats at the
beginning of the experiment. All animals survived for greater than 3 months and
no toxic effects (neurological deficits, weight loss, failure to thrive, or wound healing
problems) were observed.
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Figure 5-10: Release of doxorubicin hydrochloride into water
5.7 Immunohistochemical TUNEL Stain
TUNEL staining was conducted to assess the cytotoxicity of TMZ in vivo. Brain tissue
samples were exposed to staining reagents and the number of TUNEL-positive cells in
each sample was counted. Brain tissue sections were cut ipsilateral and contralateral
to the location of the implanted devices in order to understand the significance of
device location and drug distribution in the brain. Ipsilateral section cuts were made
on the same side as the implanted device and contralateral section cuts were made on
the opposite side of the brain. Results from the first in vivo survival study showed that
the LCP-TMZ treatment group had higher ipsilateral TUNEL-positive cell counts
than all other experimental groups. LCP-TMZ and TMZ-polymer wafer groups had
statistically similar contralateral TUNEL-positive cell counts that were larger than
control, blank LCP, and oral TMZ TUNEL-positive cell counts. Results from the
second in vivo survival study also showed that the LCP-TMZ treatment group had
higher ipsilateral TUNEL-positive cell counts than all other experimental groups.
Total TUNEL-positive cell counts (ipsilateral+contralateral) showed that tissue
samples from the LCP-TMZ treated rodent group from the first and second in vivo ex-
periments had the largest number of TUNEL-positive cells. This number was higher
than both the oral TMZ and TMZ-polymer composite wafer treatment groups. Con-
trol and blank LCP microcapsule groups showed the lowest total number of TUNEL-
positive cells.
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Chapter 6
Discussion
6.1 Temozolomide Stability and Solubility
Temozolomide is known to be more stable and soluble under acidic conditions (pH<5)
than in basic conditions (pH>7) [14]. Experimental results showed that TMZ was most
stable in pH 7 water with a half-life of 99 hours (when compared to its stability in
PBS and FBS). It is also important to note that the IV formulation of temozolomide
developed by Schering-Plough is reconstituted with an aqueous buffer to form a solu-
tion with an acidic pH of 4 in order to increase the drug's stability in solution. The
PBS used for TMZ stability experiments had a pH of 7.4 but TMZ showed a much
shorter half-life of five hours in PBS than in water. Pre-clinical stability studies by
Denny and Stevens have reported half-life values ranging from 1.24 to 1.38 hours for
TMZ in aqueous phosphate buffer[48, 49]. Phosphate buffers used in those studies
had a similar pH as the PBS used in this current work (pH=7.0-7.4). The different
TMZ half-life values in solutions with similar pH values suggests that TMZ stability
is not solely pH-dependent.
PBS contains inorganic salts that are used to maintain a constant pH and ion
concentrations and osmolality that are tailored to match those of the human body.
The PBS used in this work is formulated with monopotassium phosphate, sodium
chloride, anhydrous disodium phosphate, and has an osmolality of 287 mOsm. It is
not known what salt concentrations were used in the pre-clinical TMZ stability studies
performed by Denny and Stevens but ionic strength seems to play a role in decreasing
the stability of TMZ in solution. The decreased stability of TMZ in biologically
relevant solvents such as PBS and FBS in comparison to its stability in water is an
important issue that directly affects the design of drug delivery microcapsules and
requires strict analysis of the in vitro release kinetics of TMZ from these devices.
Formulation of TMZ with an organic acid offers one way to increase the stability of
drug in the microcapsule reservoir. This formulation method, however, is not without
its own drawbacks, most important of which is the decrease in drug payload associated
with co-formulation.
Experimental work performed in this thesis showed that TMZ was most soluble
(11 mg/ml) in pH 3 buffer. It was thought that by formulating TMZ with an acidic
molecule inside the microcapsule reservoir, we would be able to achieve greater drug
stability and solubility. Greater solubility would allow for faster release kinetics for a
given orifice size and higher concentrations of drug delivered to the tumor bed. The
improved stability within the reservoir would improve the extent of release as less
drug would degrade before diffusing out of the device. The maximum solubility only
improved by approximately 30% from pH 7 water to its maximum at pH 3. Previous
calculations showed that TMZ drug payload was one of the main limitations of the
microcapsule delivery system, and this marginal improvement in solubility did not
justify the loss of drug payload associated with co-formulation of TMZ with an organic
acid.
6.2 In Vitro Temozolomide Drug Release Kinetics
6.2.1 Temozolomide-Polymer Composite Wafers
A total TMZ payload of 3.75mg was released from polymer wafers into water after
62 hours. Drug release began to plateau after this time period. Similar drug release
behavior was seen by Brem et al. The total TMZ release from polymer-drug compos-
ite wafers measured by the Brem group was 3.5mg[30]. The discrepancies in the drug
release data between our group and Brem's may be due to slight variations in total
drug payloads (the polymer wafers are loaded 50% (w/w) with TMZ by the solvent
method[30]) between wafers. The solvent method of loading drug into polymer com-
posite devices requires solutionization of TMZ. This can cause drug degradation before
TMZ is loaded into the polymer matrix, effectively reducing the final drug payload.
The detection methods between the two experiments were also different, the Brem
group used radioactive liquid scintillation counting (LSC) to quantify tritium-labeled
TMZ, and our group used HPLC for non-radioactive labeled TMZ. The total amount
of drug released by the end of each experiment was similar despite the differences in
experimental setup and quantitative analysis methods.
6.2.2 Temozolomide-loaded Microcapsule Devices
Single and multiple-hole drug delivery microcapsules showed similar in vitro drug
release behavior. Both types of devices exhibited close agreement with theoretical
mass flow rate calculations for the first 100 hours of drug release. The release rates
of the single and multiple-hole microcapsules began to plateau after this time. This
plateau is due to a decrease in the chemical driving force for diffusion and drug
degradation. Our use of Fick's First Law of Diffusion assumes that the microcapsule
reservoir is completely saturated with drug and the outside environment is at sink
conditions throughout the entire period of drug release. This allows for simplification
of the diffusion equation (a linear concentration gradient that does not change with
time) that still captures the majority of the experimentally-determined drug release
behavior. The actual behavior of TMZ over the entire course of drug release is not as
straightforward. The driving force for diffusion decreases as drug is released from the
microcapsule reservoir because the reservoir is no longer completely saturated with
drug. The concentration profile between the reservoir and outside environment begins
to approach the same value as drug is released, and the mass flow rate across the device
orifice decreases. This results in slower drug diffusion than predicted theoretically
from Fick's First Law. One way to express this change in drug concentration with time
is to use Fick's Second Law of Diffusion. This equation takes into account changes
in drug concentration over space and time. Its application to this work is made more
complex than Fick's First Law due to the fact that specific experimentally determined
boundary conditions must be set up in order to solve the equation. Future work will
study the applicability of Fick's Second Law of Diffusion to the release kinetics of
these drug delivery microcapsules.
The stability of TMZ also has a profound impact on the in vitro release kinetics
of drug delivery microcapsules. TMZ is a prodrug that quickly degrades into the
bioactive MTIC molecule under basic conditions and in high ionic strength solvents.
In vitro release profiles of TMZ into water from microcapsule devices highlight the
importance of specifying the environment that the drug of interest is released into.
The half-life of TMZ in water is considerably greater than its half-life in PBS, FBS,
and in vivo, as mentioned previously. This accounts for the close agreement with
theory that is seen during the first 100 hours of the TMZ-water release profiles. The
current HPLC method is sensitive to TMZ and is unable to detect MTIC molecules
in solution. This is shown by the difference between theoretical release kinetics,
which assume only one type of molecule in solution (TMZ), and experimental release
of TMZ from our devices over time periods greater than 100 hours. Degradation of
TMZ due to its instability in solution accounts for the plateau in drug release over long
periods of time and also explains why 100% drug release is not seen experimentally.
Knowledge of the stability characteristics of TMZ in approximate in vivo conditions
is an excellent asset in interpreting in vitro results and designing drug delivery devices
for in vivo studies. Future work employing the use of HPLC/MS systems along with
improved analysis methods that are able to detect MTIC will allow us to characterize
the release of both TMZ and MTIC from these devices.
6.3 In Vivo Rodent Experiments
6.3.1 Fibrous Encapsulation
Empty PLLA and LCP microcapsule devices were implanted in the flank and in-
tracranially in Fischer 344 rats. Devices were implanted for a total of 30 days. Visual
inspection confirmed that fibrous tissue was present on devices implanted in the flank
but not on devices implanted in the brain. Previous work by Lillehei et al. also showed
that PLLA drug delivery devices appeared to be inert when implanted intracranially.
This group performed histological analysis on the brain tissue surrounding the poly-
mer implants in addition to visual inspection of the explanted polymer. They found
that histologically, no macrophages, mononuclear cells, or significant histiocytic re-
sponse was present 40 days after polymer implantation [501. A mild foreign body
reaction surrounding the site of the polymer was noted, but no fibrous tissue growth
was present intracranially. Our results agree with those found in the Lillehei study,
but further histological work needs to be conducted to ascertain the reasons for the
fibrous device encapsulation that occurs in the flank but not in the brain.
The apparent lack of intracranial immune response to the microcapsule drug de-
livery system is important for two reasons: 1) It proves that the polymers used for the
microcapsule housing are non-toxic and biocompatible. 2) The lack of fibrous cap-
sule formation keeps the drug-eluting orifices from being occluded by tissue, ensuring
drug release in vivo. Long-term in vivo efficacy studies (120 days) also confirmed a
lack of fibrous tissue formation. This suggests that the polymers used for fabrication
of these microcapsule devices are biocompatible and suitable for intracranial rodent
implantation.
6.3.2 Efficacy of Locally Delivered Temozolomide
The in vivo efficacy of localized TMZ therapy was investigated against the 9L glioma
model in rodents. Results showed that the implantation of two 50% (w/w) TMZ-
polymer wafers prolonged animal survival the longest in comparison to all experi-
mental groups. These devices were implanted five days after tumor implantation.
Microcapsule devices (single and multiple-orifice) implanted on the same day as 9L
tumor showed the second-best survival benefit in tumor-challenged rats. Both local-
ized drug delivery systems out-performed Temodar@, the current standard of care for
GBM treatment.
Polymer-drug composite wafers are capable of multi-directional drug diffusion
because the entire device surface is exposed to the tumor bed and is able to release
drug. Microcapsule devices, on the other hand, are only able to release drug from
either one orifice or five orifices. Multiple-orifice microcapsules extended median
animal survival by two weeks when compared with single-orifice devices. The faster
drug release kinetics provided by the multiple-orifice microcapsules (proven by in vitro
drug release experiments) deliver a larger drug payload to the tumor than single-orifice
devices over a shorter period of time. This relatively quick release is important to
maintaining the potency of the inherently unstable TMZ molecule. Additional release
orifices can be fabricated in microcapsule reservoirs in order to approach the truly
multi-directional drug release achieved by the wafer system.
The device implantation procedure also has important ramifications on the efficacy
of localized treatment. The microcapsule dimensions were chosen for delivery of a
large drug payload from a device that is still small enough for implantation in the
rodent brain cavity. The tight dimensional tolerances between the rodent skull and the
microcapsule device along with the introduction of a growing 9L tumor mass causes
brain damage due to increased intracranial pressure (mass effect). This increase in
pressure is a common manifestation in GBM patients and is one of the primary reasons
for tumor resection surgery. The detrimental effect of increased intracranial pressure
is shown by the relatively quick animal deaths present in the blank microcapsule
device groups.
The effect of decreased "free volume" between the microcapsule drug release ori-
fice and brain tissue due to growing tumor also explains why multiple-orifice devices
performed better than single-orifice devices, and why day zero microcapsule devices
performed better than day five microcapsules devices. The hypothesis is that grow-
ing tumor causes increased intracranial pressure, as noted in the previous paragraph,
and this tissue mass also occludes the drug-releasing orifice in single-hole devices.
This occlusion occurs because the devices are implanted with the orifice facing the
tumor. Multiple-orifice devices and polymer wafers are capable of multi-directional
drug release that is able to avoid the occlusion caused by the growing tissue mass. Ex-
planted single-orifice devices were found to have residual TMZ left in the reservoir and
multi-orifice devices were completely empty. Day zero microcapsules out-performed
day five devices because the tumor mass on day zero was not as large as the tu-
mor mass present on day five. The efficacy of localized drug delivery devices in this
work is directly related to their size and ability for multi-directional drug release.
The progressive improvement in animal survival from single-orifice microcapsules to
multiple-orifice microcapsules to polymer wafers confirms this. It may also be ben-
eficial to move to larger animal models where there is more intracranial space for
microcapsule implantation and lower probability of orifice occlusion.
The need for delivery of high drug concentrations to GBM locally was the mo-
tivating factor of this work, and the PLLA and LCP microcapsule devices devel-
oped by our group look to improve upon the successes of the Gliadel@ wafer and
the polymer-matrix composite wafers fabricated by the Brem group at Johns Hop-
kins University[30] [8]. The microcapsule system delivers more than twice the drug
payload as the TMZ-polymer matrix wafers in a similar volume that is suitable for
intracranial implantation. Microcapsule devices are also capable of delivering solid
or liquid drug formulations, an ability that polymer-composite wafer systems do not
currently possess. This allows for highly versatile and tunable drug delivery with the
possibility of delivering a wide range of therapeutic compounds to brain tumors and
other human diseases.
6.4 Immunohistochemical TUNEL Stain
Animals treated with TMZ showed the largest number of TUNEL-positive cells when
compared to both control groups (tumor only and blank LCP). This behavior is to be
expected because TMZ is known to cause single and double stranded DNA breaks, or
"nicks," and animals that were not exposed to TMZ (both control groups) showed very
low levels of TUNEL-positive cells. The relatively low TUNEL staining present in the
oral TMZ group is probably due to low partitioning of TMZ from systemic circulation
to the brain, with only an estimated 35% of the oral TMZ dosage reaching the brain.
The higher drug payload in the LCP microcapsule devices (12mg) may explain why
more TUNEL-positive cells were found in this group versus the TMZ wafer group.
One interesting observation from the TUNEL stain experiment is that the results
for LCP-TMZ microcapsules versus polymer wafers do not correlate with the animal
survival studies. The animals in the LCP-TMZ group had a higher overall number
of TUNEL-positive cells than the TMZ-polymer wafer group, but longer survival was
observed in the wafer group. One possible reason for this increase in survival may be
due to insufficient tumor targeting. The cytotoxicity of TMZ is non-specific to cancer
cells due to the fact that all cells are affected by DNA damage induced by the drug.
Localized delivery of TMZ increases the exposure of tumor cells to drug while avoiding
the cytotoxic effects imposed on normal healthy cells by TMZ. The total number of
TUNEL-positive cells is certainly higher in the LCP-TMZ group than in the wafer
group, but in addition to damaged 9L cells, these numbers include healthy brain cells
that have been damaged by TMZ and are also undergoing apoptosis. The overall
effect is that more cells (healthy and cancerous) may be damaged in the LCP-TMZ
group, causing brain/tumor damage and death.
6.5 Doxorubicin Hydrochloride Studies
Doxorubicin hydrochloride was chosen for experimentation based on its unaccept-
able side-effects when administered systemically (congestive heart failure in 20% of
patients), proven activity against GBM, and significantly reduced total local drug
payload in comparison to TMZ. Initial DOX studies included drug efficacy studies
against 9L glioma cells in vitro, DOX release studies from microcapsules in vitro, and
DOX toxicity studies in Fischer 344 rodents. Our in vitro efficacy experiments con-
firmed that 9L glioma cells were sensitive to DOX at low concentrations of 0.1ug/ml.
This allowed us to move forward to develop microcapsules that were capable of deliv-
ering DOX locally in vivo. In vitro drug release kinetics and in vivo toxicity studies
suggested that local delivery of 1mg DOX over two weeks was safe and well-tolerated
in our rodent model. Future studies will examine the efficacy of localized DOX de-
livery in comparison with systemic administration of Doxil@, the current standard of
care formulation of DOX.
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Chapter 7
Conclusions and Future Work
The work conducted in this thesis has demonstrated that polymer microcapsule de-
vices are capable of releasing chemotherapeutic molecules in vitro at rates similar
to theoretical values calculated from Fick's First Law of Diffusion. The polymers
used in the manufacture of these devices are both biocompatible (LCP and PLLA)
and biodegradable (PLLA) when implanted intracranially in a rodent animal model.
Molecular histochemical analysis and MTT assay confirms the ability of drugs used
in this thesis to cause cytotoxic DNA damage in cell nuclei. I have also shown that
implantable drug delivery devices are capable of significantly prolonging survival in
9L glioma-challenged rodents in comparison with systemic delivery methods. Issues
related to unattainable drug payloads needed for complete TMZ therapy led to the
selection of doxorubicin as the second chemotherapeutic of interest. In vitro release
experiments proved that microcapsule devices are able to release DOX payloads reli-
ably. Further in vitro testing of these devices along with in vivo DOX dose escalation
trials will allow for future in vivo rodent efficacy studies. Work is ongoing to produce
a syringe injectable multiple reservoir version with the capability of releasing a range
of therapeutic compounds in solid or liquid formulations. We have chosen to focus
on treatment of glioblastoma multiforme in this work but through knowledge of clin-
ically relevant dosing schedules, chemotherapeutic solubility and stability, and with
minor changes in device orifice diameter, it will be possible to use these drug delivery
microcapsules to treat a range of human diseases.
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